{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:15:49Z","timestamp":1794863749141,"version":"4.9.1"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203492"],"award-info":[{"award-number":["82203492"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22175144"],"award-info":[{"award-number":["22175144"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2022YFS0625"],"award-info":[{"award-number":["2022YFS0625"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105413","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:02:26Z","timestamp":1780300946000},"page":"105413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Bile acids in the tumor immune microenvironment of hepatocellular carcinoma: Mechanisms of immunotherapy resistance and therapeutic opportunities"],"prefix":"10.1016","volume":"225","author":[{"given":"Songlin","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shurong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinya","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2026.105413_bib1","article-title":"A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma","volume":"6","author":"Balcar","year":"2023","journal-title":"JHEP Rep."},{"key":"10.1016\/j.critrevonc.2026.105413_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3389\/fcell.2020.00709","article-title":"Hepatic stellate cells and hepatocarcinogenesis","volume":"8","author":"Barry","year":"2020","journal-title":"Front. Cell. Dev. Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105413_bib3","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.1700183","article-title":"The bile acid receptor GPBAR1 regulates the M1\/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from murine colitis","volume":"199","author":"Biagioli","year":"2017","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105413_bib4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jcmgh.2019.06.003","article-title":"GPBAR1 functions as gatekeeper for liver NKT cells and provides counterregulatory signals in mouse models of immune-mediated hepatitis","volume":"8","author":"Biagioli","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105413_bib5","doi-asserted-by":"crossref","DOI":"10.1021\/jacs.5c18912","article-title":"Chemical proteomics reveals regulation of bile salt hydrolases via oxidative post-translational modifications","author":"Bracken","year":"2026","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105413_bib6","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer Journal Clinicians"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105413_bib7","doi-asserted-by":"crossref","first-page":"G108","DOI":"10.1152\/ajpgi.00356.2017","article-title":"FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection","volume":"317","author":"Cao","year":"2019","journal-title":"Am. J. Physiol. -Gastrointest. Liver Physiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105413_bib8","first-page":"189","article-title":"A first-in-human phase 1\/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors","volume":"41","author":"Chan","year":"2022","journal-title":"Journal Experimental & Clinical Cancer Research CR"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105413_bib9","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000217","article-title":"Bile acids promote the development of HCC by activating inflammasome","volume":"7","author":"Chen","year":"2023","journal-title":"Hepatol. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105413_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105413_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1113785","article-title":"GPBAR1 is associated with asynchronous bone metastasis and poor prognosis of hepatocellular carcinoma","volume":"12","author":"Chen","year":"2023","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105413_bib12","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M110.004945","article-title":"Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma","volume":"10","author":"Chen","year":"2011","journal-title":"Mol. Cell. Proteom."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105413_bib13","article-title":"Immunotherapy for hepatocellular carcinoma","volume":"6","author":"Childs","year":"2024","journal-title":"JHEP Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105413_bib14","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41598-024-84368-2","article-title":"PNMA1 is a novel immune modulator and therapeutic target in hepatocellular carcinoma linked to bile acid metabolism","volume":"15","author":"Chu","year":"2025","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105413_bib15","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.4254\/wjh.v14.i9.1730","article-title":"Bile acids as drivers and biomarkers of hepatocellular carcinoma","volume":"14","author":"Colosimo","year":"2022","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105413_bib16","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.95191.3","article-title":"Emerging role of oncogenic \u00df-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma","volume":"13","author":"Dantzer","year":"2024","journal-title":"eLife"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105413_bib17","article-title":"Glycodeoxycholic acid inhibits hepatocellular carcinoma by driving M1 polarization of macrophages via the S1PR2\u2013NF-\u03baB\u2013NLRP3 pathway","volume":"8","author":"Deng","year":"2026","journal-title":"JHEP Rep."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105413_bib18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","article-title":"Metabolic barriers to cancer immunotherapy","volume":"21","author":"DePeaux","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105413_bib19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s44355-025-00018-y","article-title":"Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models","volume":"2","author":"Desert","year":"2025","journal-title":"npj Gut Liver"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105413_bib20","article-title":"BAAT away liver cancer: conjugated bile acids impair T cell function in hepatocellular carcinoma immunotherapy","volume":"7","author":"Detwiler","year":"2025","journal-title":"Immunometabolism (Cobham Surrey)"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105413_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000545","article-title":"Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis","volume":"8","author":"El-Serag","year":"2024","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.critrevonc.2026.105413_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103902","article-title":"Deciphering the possible reciprocal loop between hepatic stellate cells and cancer cells in the tumor microenvironment of the liver","volume":"182","author":"Ezhilarasan","year":"2023","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105413_bib23","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/1078-0432.CCR-24-1834","article-title":"Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven malignancies","volume":"30","author":"Facchinetti","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105413_bib24","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/jcsm.12798","article-title":"Bile acid metabolism dysregulation associates with cancer cachexia: roles of liver and gut microbiome","volume":"12","author":"Feng","year":"2021","journal-title":"J. Cachex. Sarcopenia Muscle"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105413_bib25","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.molmed.2015.09.001","article-title":"Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders","volume":"21","author":"Fiorucci","year":"2015","journal-title":"Trends Mol. Med."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105413_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cells13181580","article-title":"Current landscape and evolving therapies for primary biliary cholangitis","volume":"13","author":"Fiorucci","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105413_bib27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","article-title":"Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105413_bib28","article-title":"Metabolic reprogramming in hepatocellular carcinoma: mechanisms of immune evasion and therapeutic implications","volume":"16","author":"Gao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105413_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.711448","article-title":"Norcholic acid promotes tumor progression and immune escape by regulating farnesoid X receptor in hepatocellular carcinoma","volume":"11","author":"Gong","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105413_bib30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105413_bib31","article-title":"Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma","volume":"36","author":"Guo","year":"2022","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"issue":"33","key":"10.1016\/j.critrevonc.2026.105413_bib32","doi-asserted-by":"crossref","first-page":"34606","DOI":"10.18632\/oncotarget.5314","article-title":"FXR induces SOCS3 and suppresses hepatocellular carcinoma","volume":"6","author":"Guo","year":"2015","journal-title":"Oncotarget"},{"issue":"29","key":"10.1016\/j.critrevonc.2026.105413_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg2697","article-title":"D-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma","volume":"9","author":"Han","year":"2023","journal-title":"Sci. Adv."},{"issue":"7785","key":"10.1016\/j.critrevonc.2026.105413_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","article-title":"Bile acid metabolites control Th17 and Treg cell differentiation","volume":"576","author":"Hang","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105413_bib35","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.molonc.2014.10.004","article-title":"Biomarker validation and testing","volume":"9","author":"Hayes","year":"2015","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105413_bib36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/cmi.2015.112","article-title":"Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells","volume":"13","author":"Horst","year":"2016","journal-title":"Cell. Mol. Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105413_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109726","article-title":"Gut microbiota-mediated secondary bile acids regulate dendritic cells to attenuate autoimmune uveitis through TGR5 signaling","volume":"36","author":"Hu","year":"2021","journal-title":"Cell. Rep."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105413_bib38","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.7150\/ijbs.71287","article-title":"Lithocholic acid inhibits dendritic cell activation by reducing intracellular glutathione via TGR5 signaling","volume":"18","author":"Hu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105413_bib39","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105413_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102560","article-title":"Bile acid accumulation induced by miR-122 deficiency in liver parenchyma promotes cancer cell growth in hepatocellular carcinoma","volume":"36","author":"Huang","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105413_bib41","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ccell.2025.05.017","article-title":"Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma","volume":"43","author":"Huang","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105413_bib42","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1186\/s12967-023-04716-0","article-title":"Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC)","volume":"21","author":"Huang","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105413_bib43","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41698-025-00960-3","article-title":"Bifidobacterium boosts anti-PD-1 effectiveness through JAK pathway in hepatocellular carcinoma","volume":"9","author":"Huo","year":"2025","journal-title":"NPJ Precis. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105413_bib44","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.apsb.2020.09.004","article-title":"Precise delivery of obeticholic acid via nanoapproach for triggering natural killer T cell-mediated liver cancer immunotherapy","volume":"10","author":"Ji","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2026.105413_bib45","article-title":"Single-cell RNA sequencing and spatial transcriptomic analysis reveal a distinct population of G6PD+ cells with aberrant bile acid metabolism in hepatocellular carcinoma","volume":"17","author":"Jiang","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105413_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2026.116464","article-title":"Advancing cancer diagnosis and therapy: MXene-based biosensing and nanomedicine applications","volume":"176","author":"Kamyab","year":"2026","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105413_bib47","article-title":"Advances in green synthesis of nanoparticles for biomedical applications: Antimicrobial, antiviral, and cancer therapies","volume":"33","author":"Kamyab","year":"2026","journal-title":"Mater. Today Sustain."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105413_bib48","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbrc.2008.04.171","article-title":"Expression and function of the bile acid receptor TGR5 in kupffer cells","volume":"372","author":"Keitel","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105413_bib49","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105413_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004779","article-title":"Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"10","author":"Lee","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105413_bib51","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.chom.2021.07.013","article-title":"A bacterial bile acid metabolite modulates Treg activity through the nuclear hormone receptor NR4A1","volume":"29","author":"Li","year":"2021","journal-title":"Cell. Host & Microbe"},{"key":"10.1016\/j.critrevonc.2026.105413_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104990","article-title":"Prediagnostic plasma metabolite concentrations and liver cancer risk: A population-based study of Chinese men","volume":"100","author":"Li","year":"2024","journal-title":"eBioMedicine"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105413_bib53","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1136\/gutjnl-2021-325189","article-title":"Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma","volume":"71","author":"Liu","year":"2021","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105413_bib54","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1210\/me.2011-1383","article-title":"Hepatocarcinogenesis in FXR\u2212\/\u2212 mice mimics human HCC progression that operates through HNF1\u03b1 regulation of FXR expression","volume":"26","author":"Liu","year":"2012","journal-title":"Mol. Endocrinol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105413_bib55","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2159-8290.CD-16-0932","article-title":"Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity","volume":"7","author":"Loo","year":"2017","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105413_bib56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3892\/ijo.2022.5407","article-title":"Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (review)","volume":"61","author":"Luo","year":"2022","journal-title":"Int. J. Oncol."},{"issue":"6391","key":"10.1016\/j.critrevonc.2026.105413_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome\u2013mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"360","author":"Ma","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105413_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100920","article-title":"PI3K-CCL2-CCR2-MDSCs axis: A potential pathway for tumor clostridia-promoted CD 8+ T lymphocyte infiltration in bile tract cancers","volume":"43","author":"Ma","year":"2023","journal-title":"Neoplasia"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105413_bib59","article-title":"Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma","volume":"9","author":"Ma","year":"2019","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105413_bib60","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jcmgh.2021.04.013","article-title":"Combined ASBT inhibitor and FGF15 treatment improves therapeutic efficacy in experimental nonalcoholic steatohepatitis","volume":"12","author":"Matye","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105413_bib61","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-006-9242-8","article-title":"REporting recommendations for tumor MARKer prognostic studies (REMARK)","volume":"100","author":"McShane","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105413_bib62","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.cell.2024.02.019","article-title":"The underappreciated diversity of bile acid modifications","volume":"187","author":"Mohanty","year":"2024","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105413_bib63","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.3390\/cancers15082311","article-title":"Role of \u03b2-catenin activation in the tumor immune microenvironment and immunotherapy of hepatocellular carcinoma","volume":"15","author":"Morita","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105413_bib64","article-title":"Dielectrophoresis-based microfluidics for detection and separation of circulating tumor cells","volume":"9","author":"Najafipour","year":"2025","journal-title":"Sens. Actuators Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105413_bib65","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/ijms25010006","article-title":"Targeting farnesoid X receptor in tumor and the tumor microenvironment: Implication for therapy","volume":"25","author":"Nenkov","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105413_bib66","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1007\/s00432-020-03374-9","article-title":"Senescent hepatic stellate cells caused by deoxycholic acid modulates malignant behavior of hepatocellular carcinoma","volume":"146","author":"Nguyen","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105413_bib67","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1152\/physrev.00049.2019","article-title":"Molecular physiology of bile acid signaling in health, disease, and aging","volume":"101","author":"Perino","year":"2021","journal-title":"Physiol. Rev."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105413_bib68","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/hep4.1905","article-title":"Gut dysbiosis and fecal calprotectin predict response to immune checkpoint inhibitors in patients with hepatocellular carcinoma","volume":"6","author":"Ponziani","year":"2022","journal-title":"Hepatol. Commun."},{"issue":"10415","key":"10.1016\/j.critrevonc.2026.105413_bib69","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet (Lond. Engl. )"},{"issue":"7858","key":"10.1016\/j.critrevonc.2026.105413_bib70","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","article-title":"Cell-programmed nutrient partitioning in the tumour microenvironment","volume":"593","author":"Reinfeld","year":"2021","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105413_bib71","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jhep.2021.01.028","article-title":"STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway","volume":"74","author":"de la Rosa","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105413_bib72","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"Russell","year":"2003","journal-title":"Annu. Rev. Biochem."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105413_bib73","article-title":"Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis","volume":"6","author":"Sanchez","year":"2024","journal-title":"JHEP Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105413_bib74","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105413_bib75","article-title":"Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis","volume":"7","author":"Schulze","year":"2025","journal-title":"JHEP Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105413_bib76","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12072-022-10299-7","article-title":"Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma","volume":"16","author":"Shen","year":"2022","journal-title":"Hepatol. Int."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105413_bib77","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.3390\/cancers14092099","article-title":"Modulation of the gut microbiome to improve clinical outcomes in hepatocellular carcinoma","volume":"14","author":"Shen","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105413_bib78","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1038\/s41467-022-31141-6","article-title":"Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-\u03b2 degradation","volume":"13","author":"Shen","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105413_bib79","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","article-title":"Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: Current status and prospectives","volume":"17","author":"Shen","year":"2024","journal-title":"J. Hematol. & Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105413_bib80","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cmet.2024.09.008","article-title":"Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress","volume":"37","author":"Song","year":"2025","journal-title":"Cell. Metab."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105413_bib81","first-page":"144","article-title":"Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma","volume":"21","author":"Song","year":"2024","journal-title":"Cancer Biol. & Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105413_bib82","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/ijc.33885","article-title":"Prediagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma","volume":"150","author":"Stepien","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105413_bib83","doi-asserted-by":"crossref","first-page":"G91","DOI":"10.1152\/ajpgi.00027.2015","article-title":"Bile acids promote diethylnitrosamine-induced hepatocellular carcinoma via increased inflammatory signaling","volume":"311","author":"Sun","year":"2016","journal-title":"Am. J. Physiol. -Gastrointest. Liver Physiol."},{"issue":"38","key":"10.1016\/j.critrevonc.2026.105413_bib84","doi-asserted-by":"crossref","first-page":"12014","DOI":"10.1021\/acs.jafc.2c04817","article-title":"Nuciferine protects against high-fat diet-induced hepatic steatosis via modulation of gut microbiota and bile acid metabolism in rats","volume":"70","author":"Sun","year":"2022","journal-title":"J. Agric. Food Chem."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105413_bib85","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jhep.2022.02.030","article-title":"Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis","volume":"77","author":"Sun","year":"2022","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105413_bib86","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/hep.32758","article-title":"Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH","volume":"77","author":"Tan","year":"2023","journal-title":"Hepatol. (Baltim. Md. )"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105413_bib87","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.3390\/cancers13112648","article-title":"Association between Pre-Diagnostic Serum Bile Acids and Hepatocellular Carcinoma: The Singapore Chinese Health Study","volume":"13","author":"Thomas","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105413_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1638352","article-title":"Interplay between bile acids, gut microbiota, and the tumor immune microenvironment: Mechanistic insights and therapeutic strategies","volume":"16","author":"Tong","year":"2025","journal-title":"Front. Immunol."},{"issue":"6730","key":"10.1016\/j.critrevonc.2026.105413_bib89","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1126\/science.adl4100","article-title":"Bile acid synthesis impedes tumor-specific T cell responses during liver cancer","volume":"387","author":"Varanasi","year":"2025","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105413_bib90","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","article-title":"The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity","volume":"183","author":"Vavassori","year":"2009","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105413_bib91","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.24525","article-title":"The G-protein coupled bile acid receptor Gpbar1 (TGR5) negatively regulates hepatic inflammatory response through antagonizing nuclear factor \u03baB","volume":"54","author":"Wang","year":"2011","journal-title":"Hepatol. (Baltim. Md. )"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105413_bib92","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/vaccines13050502","article-title":"Unlocking mRNA vaccine potential in liver cancer treatment via synergistic bile acid modulation","volume":"13","author":"Wang","year":"2025","journal-title":"Vaccines"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105413_bib93","doi-asserted-by":"crossref","first-page":"12223","DOI":"10.3390\/ijms252212223","article-title":"Metabolic reprogramming of immune cells in the tumor microenvironment","volume":"25","author":"Wang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105413_bib94","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s42255-024-01037-4","article-title":"Acetate reprogrammes tumour metabolism and promotes PD-L1 expression and immune evasion by upregulating c-myc","volume":"6","author":"Wang","year":"2024","journal-title":"Nat. Metab."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105413_bib95","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.cmet.2025.01.011","article-title":"AKR1D1 suppresses liver cancer progression by promoting bile acid metabolism-mediated NK cell cytotoxicity","volume":"37","author":"Wei","year":"2025","journal-title":"Cell. Metab."},{"key":"10.1016\/j.critrevonc.2026.105413_bib96","article-title":"The role of FGF19\u2013FGFR4 signaling pathway in liver health and disease: Guardian or destroyer","author":"Wu","year":"2025","journal-title":"Genes. & Dis."},{"key":"10.1016\/j.critrevonc.2026.105413_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1033145","article-title":"Deregulated bile acids may drive hepatocellular carcinoma metastasis by inducing an immunosuppressive microenvironment","volume":"12","author":"Xia","year":"2022","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105413_bib98","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/ijc.30219","article-title":"Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis","volume":"139","author":"Xie","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105413_bib99","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1089\/jir.2012.0008","article-title":"Activation of farnesoid X receptor increases the expression of cytokine inducible SH2-containing protein in HepG2 cells","volume":"32","author":"Xu","year":"2012","journal-title":"J. Interferon & Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105413_bib100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41419-025-08393-3","article-title":"CYP8B1 inhibits hepatocellular carcinoma progression by repressing PAK4 transcription through inhibition of nuclear translocation of u-STAT1","volume":"17","author":"Xu","year":"2025","journal-title":"Cell. Death & Dis."},{"key":"10.1016\/j.critrevonc.2026.105413_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1640450","article-title":"GCDCA promotes hepatocellular carcinoma progression through S1PR2\/PI3K\/AKT-mediated polarization of M2-type macrophages","volume":"17","author":"Xue","year":"2026","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105413_bib102","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41423-023-01026-9","article-title":"Emerging roles of bile acids in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma","volume":"20","author":"Xun","year":"2023","journal-title":"Cell. & Mol. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105413_bib103","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","article-title":"Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105413_bib104","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13046-023-02659-4","article-title":"FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling","volume":"42","author":"Yang","year":"2023","journal-title":"J. Exp. & Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105413_bib105","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/mc.23869","article-title":"Levels of bile acid metabolism are associated with alterations of gut microbes in hepatocellular carcinoma","volume":"64","author":"Yang","year":"2025","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.critrevonc.2026.105413_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118117","article-title":"Small-molecule FGFR-targeted medicinal chemistry: Advances since 2020 and future perspectives","volume":"300","author":"Yue","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105413_bib107","doi-asserted-by":"crossref","first-page":"11432","DOI":"10.1039\/D4FO03353A","article-title":"Abnormal enterohepatic circulation of bile acids caused by fructooligosaccharide supplementation along with a high-fat diet","volume":"15","author":"Zeng","year":"2024","journal-title":"Food & Funct."},{"key":"10.1016\/j.critrevonc.2026.105413_bib108","article-title":"The alterations in and the role of the Th17\/treg balance in metabolic diseases","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105413_bib109","first-page":"2989","article-title":"RNA methylation regulators contribute to poor prognosis of hepatocellular carcinoma associated with the suppression of bile acid metabolism: A multi-omics analysis","volume":"12","author":"Zhang","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105413_bib110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2014.02.010","article-title":"The critical role of myeloid-derived suppressor cells and FXR activation in immune-mediated liver injury","volume":"53","author":"Zhang","year":"2014","journal-title":"J. Autoimmun."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105413_bib111","first-page":"1142","article-title":"Bile acids and liver cancer: Molecular mechanism and therapeutic prospects","volume":"17","author":"Zhang","year":"2024","journal-title":"Pharm. (Basel Switz. )"},{"key":"10.1016\/j.critrevonc.2026.105413_bib112","article-title":"TBA-MLR score: A metabolic-immune prognostic biomarker for postoperative hepatocellular carcinoma","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Immunol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:58:02Z","timestamp":1787108282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":112,"alternative-id":["S1040842826003008"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105413","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bile acids in the tumor immune microenvironment of hepatocellular carcinoma: Mechanisms of immunotherapy resistance and therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105413","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105413"}}